Product Information
VIMPAT 100 MG TABLET is a brand product labeled by UCB, Inc., priced at $18.5366 per EA under NDC 00131247860. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 28, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lacosamide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100 mg/1
Manufacturer
UCB, Inc.NDC
00131247860
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LACOSAMIDEApproval Type
New Drug (NDA)
FDA Application
NDA022253FDA Approved
10/28/2008
TE Code
AB
On Market Since
5/26/2009
Pharmacological Classes
Price Statistics
The NADAC for VIMPAT 100 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 116.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $18.5366 per EA |
|---|---|
| All-time high | $18.5994 (Jul 15, 2026) |
| All-time low | $8.5753 (Nov 28, 2013) |
| 52-week high | $18.5994 |
| 52-week low | $18.0441 |
| Median price | $14.2108 |
| Average price | $14.1432 |
| Largest weekly change | +9.9% (Jan 8, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
UCB, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lacosamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VIMPAT 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VIMPAT 100 MG TABLET, manufactured by UCB, Inc., is $18.5366 per EA (NDC 00131247860), effective Sep 30, 2026.
How has the price of VIMPAT 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for VIMPAT 100 MG TABLET has risen 116.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VIMPAT 100 MG TABLET?
Since Nov 28, 2013, the NADAC for VIMPAT 100 MG TABLET has ranged from a low of $8.5753 (Nov 28, 2013) to a high of $18.5994 (Jul 15, 2026), with a median of $14.2108 per EA.
Are there cheaper alternatives to VIMPAT 100 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LACOSAMIDE 100 MG TABLET, is $0.1743 per EA — about 99% below VIMPAT 100 MG TABLET.
Who manufactures VIMPAT 100 MG TABLET?
VIMPAT 100 MG TABLET (NDC 00131247860) is labeled by UCB, Inc., and CMS classifies it as a brand product.